{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:08:24Z","timestamp":1777421304899,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>\n                    Background: Impaired glucose regulation posttransplantation can affect allograft survival and may lead to the development of posttransplant diabetes mellitus (PTDM). Objectives: The primary purpose of this study is to assess the difference in insulin burden between liver transplant patients who develop PTDM and patients who do not. Methods: This was a single-center, retrospective study. Adult liver transplant recipients transplanted between January 1, 2005, and August 1, 2013, were included. PTDM was defined as: (1) use of an oral antihyperglycemic agent for \u226530 consecutive days after transplant, (2) use of insulin \u226530 consecutive days after transplant, or (3) hemoglobin A\n                    <jats:sub>1C<\/jats:sub>\n                    \u22656.5 any time after transplant. Results: Of the 114 patients included, 48 (42%) developed PTDM. The average 24-hour insulin requirement on the medical floors was 17.2 \u00b1 14.5 units in the PTDM group and 11.3 \u00b1 12.2 units in the PTDM-free group; P = 0.02. The average blood glucose level on the medical floor was 184.7 \u00b1 31.5 mg\/dL in the PTDM group and 169.3 \u00b1 31.4 mg\/dL in the PTDM-free group; P = 0.013. Multivariate analysis revealed that experiencing rejection was positively associated with the development of PTDM: adjusted odds ratio (AOR) = 3.237; 95% CI = 1.214-8.633. Basiliximab was negatively associated with the development of PTDM: AOR = 0.182; 95% CI = 0.040-0.836. Conclusion: Univariate analyses suggest that insulin burden is a positive risk factor for the development of PTDM; this association is lost in multivariate analyses. Rejection was a positive predictor, and use of basiliximab was a negative predictor for the development of PTDM.\n                  <\/jats:p>","DOI":"10.1177\/1060028015627662","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T21:03:49Z","timestamp":1454619829000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Posttransplantation Diabetes Mellitus After Liver Transplantation"],"prefix":"10.1177","volume":"50","author":[{"given":"Kristin E.","family":"Linder","sequence":"first","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Baker","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs and Farmington, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rochon","sequence":"additional","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"May","sequence":"additional","affiliation":[{"name":"Saint Francis Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Sheiner","sequence":"additional","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer T.","family":"Martin","sequence":"additional","affiliation":[{"name":"Hartford Hospital, Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"bibr1-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000250361.60415.96"},{"key":"bibr2-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-012-0346-8"},{"key":"bibr3-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318293fcf8"},{"key":"bibr4-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2013.10.006"},{"key":"bibr5-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12391"},{"key":"bibr6-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12103"},{"key":"bibr7-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.03.009"},{"key":"bibr8-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.12.007"},{"key":"bibr9-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12850"},{"key":"bibr10-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.12.027"},{"key":"bibr11-1060028015627662","volume-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus","author":"World Health Organization","year":"2006"},{"key":"bibr12-1060028015627662","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S067"},{"key":"bibr13-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12850"},{"key":"bibr14-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250328"},{"key":"bibr15-1060028015627662","first-page":"166","volume":"28","author":"Benhamou PY","year":"2002","journal-title":"Diabetes Metab"},{"key":"bibr16-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.20602.x"},{"key":"bibr17-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109270-00015"},{"key":"bibr18-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181d2fec1"},{"key":"bibr19-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31818fff64"},{"key":"bibr20-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20307"},{"key":"bibr21-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12100"},{"key":"bibr22-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.30302"},{"key":"bibr23-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.09.169"},{"key":"bibr24-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000282914.20578.7b"},{"key":"bibr25-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.010"},{"key":"bibr26-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.10.110"},{"issue":"3","key":"bibr27-1060028015627662","first-page":"349","volume":"10","author":"Khalili M","year":"2004","journal-title":"Transpl"},{"key":"bibr28-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.06.084"},{"key":"bibr29-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31816f1b7c"},{"key":"bibr30-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21010"},{"key":"bibr31-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1177\/152692480601600204"},{"key":"bibr32-1060028015627662","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.10.029"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015627662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028015627662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015627662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:12Z","timestamp":1777374972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028015627662"}},"subtitle":["Assessment of Insulin Administration as a Risk Factor"],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1177\/1060028015627662"],"URL":"https:\/\/doi.org\/10.1177\/1060028015627662","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}